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intolerance, weakness, labored breathing, cough, cyanosis, respiratory crackles, and jugular venous distension; however, these signs are nonspecific for CHF. A third heart sound has somewhat greater specificity for CHF as documented in dogs with experimentally induced disease 5 but lacks diagnostic sensitivity. Thoracic radiography is the most commonly applied diagnostic test for CHF in dogs 4 and people 6, 7 and is often considered the clinical gold standard in dogs with compatible clinical and echocardiographic findings. However, other objective diagnostic methods are emerging, including analysis of circulating NT-proBNP concentration 1, 8 and application of Doppler echocardiographic methods that predict high ventricular filling pressures. [9] [10] [11] Moreover, respiratory rate has long been known to be clinically useful in the assessment of CHF status, and the relationship between respiratory rate and total lung water content has been documented in dogs with experimentally induced disease. 12,a Several clinical studies 1, 2, 8, 9, 11, [13] [14] [15] [16] [17] [18] [19] [20] in dogs with MVD and DCM have considered the diagnostic usefulness of respiratory rate, natriuretic peptide concentrations, and Doppler echocardiographic indices for identification, staging, and prognosis of cardiac disease; prediction of presence or absence of CHF; and the differentiation of CHF from primary respiratory disease. It is not known, however, whether these tests also can be used to guide or monitor preload-reducing treatments in dogs with CHF. Specifically, we do not know whether such variables can verify the relief of venous congestion or guide therapeutic decisions. Accordingly, the purpose of the prospective study reported here was to determine the effects of treatment on respiratory rate, natriuretic peptide concentrations, and Doppler echocardiographic indices of left ventricular filling pressures in dogs with recent onset of CHF. Our hypotheses were that respiratory rate, NT-proBNP concentration, and selected Doppler echocardiographic variables of left ventricular diastolic function and filling change in a predictable manner following resolution of spontaneous left-sided CHF; quantitative decision thresholds based on the change of such variables can be identified; and there is nonuniformity between dogs with MVD and DCM with regard to the specific predictive variables and the decision thresholds for identifying successful treatment of CHF.
Materials and Methods
The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee and the Review Board of The Ohio State University Department of Veterinary Clinical Sciences. Informed consent was obtained from every dog owner.
Dogs and group assignment-Sixty-three clientowned dogs with MVD and DCM were evaluated prospectively during a period of 2 years (2007 through 2008). Dogs were determined to be affected with MVD or DCM by use of standard clinical evaluation criteria and detailed echocardiographic studies. Dogs with atrial fibrillation, systemic hypertension (systolic blood pressure > 170 mm Hg), and evidence of concomitant diseases were excluded from the study. Prior treatment with an angiotensin-converting enzyme inhibitor, spironolactone, or carvedilol was permitted in dogs with preclinical disease, and prior treatment with furosemide was permitted in dogs with CHF at the time of the baseline examination. Dogs were examined first at baseline (examination 1) and again within 2 weeks following the baseline examination (examination 2).
The specific diagnosis of interest was related to the presence or absence of CHF at the time of the 2 examinations. For this purpose, radiographic interpretation by radiologists who were blinded to the identity of the dogs was used as the reference standard for the diagnosis of CHF. Based on clinical, echocardiographic, and radiographic findings, dogs were eventually assigned to 1 of 5 groups for statistical analyses as follows: group 1, dogs with preclinical MVD with no evidence of CHF at either examination; group 2, dogs with MVD and CHF evident at examination 1 but resolved CHF at examination 2; group 3, dogs with MVD and CHF evident at both examinations; group 4, dogs with preclinical (occult) DCM with no evidence of CHF at either examination; and group 5, dogs with DCM and CHF evident at examination 1 but resolved CHF at examination 2.
Clinical examinations-All dogs underwent a thorough physical examination, noninvasive measurement of systolic blood pressure, b thoracic radiography, c-f blood biochemical analyses, and 2-D, M-mode, and Doppler echocardiographic studies g at both examinations. Heart rate and respiratory rate were measured during initial physical examination and determined as the number of beats or breaths per minute, respectively. If respiratory rate could not be obtained because of panting, dogs were reassessed within 1 hour to obtain a definitive rate. Preexisting treatments were not changed in dogs without clinical signs of CHF (groups 1 and 4) between examinations 1 and 2. All possible attempts were made to stabilize the dogs with CHF (groups 2, 3, and 5). Drugs and procedures commonly used in the treatment of dogs with CHF 4 were applied. Overtly stressed dogs with and without CHF were sedated upon arrival at the hospital with acepromazine (0.025 to 0.050 mg/kg [0.011 to 0.023 mg/lb], IM), butorphanol (0.15 to 0.25 mg/kg [0.068 to 0.114 mg/lb], IM), or both.
Thoracic radiography-Thoracic radiographs were obtained in 3 imaging planes (right lateral, left lateral, and ventrodorsal projections) prior to echocardiography at each examination. Radiographs were first assessed by the attending clinician to guide the treatment of CHF if needed. However, for final radiographic diagnosis and definitive group assignment (ie, CHF absent or CHF present), images were reassessed by 2 board-certified radiologists (VFS and LJZ) who were blinded to the dog' s identification and other relevant clinical data. A radiographic composite CHF score, including criteria for left atrial enlargement (none = 0 points, mild = 1 point, and moderate to severe = 3 points), pulmonary venous congestion (none = 0 points and present = 3 points), pulmonary infiltrates compatible with cardiogenic edema (mild interstitial = 1 point, diffuse interstitial = 2 points, and alveolar = 3 points), and pleural effusion (absent = 0 points and present = 1 point), was also used to quantify the subjective diagnosis of CHF. 20 The final radiographic assessment revealed a numeric radiographic CHF score (score = 0 to 2, CHF not likely; score = 3 to 4, CHF possible; and score > 4, CHF likely) and a qualitative binary variable (CHF absent or CHF present). After interpretation of films, results of the 2 readers were compared. If there was disagreement with regard to the principal diagnosis (CHF absent or CHF present), the investigators reassessed the images in question and collectively decided on a final diagnosis.
Collection of blood and analysis of natriuretic peptide concentrations-At each examination, 5 mL of blood was collected from the jugular vein of each dog directly into tubes for serum collection. After 20 minutes of storage at room temperature (22° to 24°C), samples were centrifuged at 3,000 X g for 10 minutes at 5°C and further processed within 15 minutes. The serum was harvested, divided into four 0.5-mL aliquots, transferred into plastic cryotubes, and stored at -80°C for a maximum of 4 weeks until analysis. Two aliquots of each sample were shipped on dry ice to the reference laboratory h where batched analysis was done once a month. Assays were run in duplicate, and the mean of the 2 values was used for final data analysis. Serum NT-proANP and serum NT-proBNP concentrations were determined by use of commercial test kits (sandwich enzyme immunoassays) with antibodies raised against human NT-proANP31-67, i canine NTproBNP25-41 (capture antibody), and canine NT-proB-NP1-22 (detection antibody).
j The detection limits were 50 pmol/L for the NT-proANP assay and 42 pmol/L for the NT-proBNP assay. The intra-assay coefficients of variation were < 10% for the NT-proANP assay and < 15% for the NT-proBNP assay, as reported by the manufacturer.
Echocardiography-Transthoracic 2-D, M-mode, and Doppler echocardiographic examinations were performed with the dogs in right and left lateral recumbency by (102 examinations) or under direct supervision of (23 examinations) a single investigator (KES) using a digital ultrasonography system with a transducer array of 3.5-MHz nominal frequency. 9, 11 Sweep speed during recordings was 100 to 150 mm/s. Two-dimensional cine loops and Doppler echocardiographic tracings were recorded and stored on the internal hard drive of the echocardiograph or on magneto-optical disk. A simultaneous 1-lead ECG was recorded. Heart rate was calculated from the preceding R-to-R interval on the ECG. Measurements were obtained from digital still images as a mean of 5 to 12 consecutive cardiac cycles, irrespective of respiratory phase. All measurements were performed offline by 1 trained observer (TMH) who was blinded to the dog' s identity and prior findings.
Echocardiographic data acquisition and analysis-For the purpose of this study, 16 variables were measured or calculated as recently described. 9, 11, 20, 21 In brief, from right parasternal long-axis recordings, the maximum left atrial craniocaudal (septal-to-free wall) dimension 21 and the end-diastolic dimension of the aortic root were measured by use of imaging views optimized for the left atrial or the left ventricular outflow tract and inner edge projections. From a left apical 3-chamber view, IVRT was measured as the period from the Doppler signal of aortic valve closure to the beginning of the E wave with a pulsed-wave sample volume of 6 to 10 mm placed in an intermediate position between the left ventricular inflow and outflow tracts. Transmitral flow was recorded from the left apical 4-chamber view with a pulsed-wave sample volume of 2 mm placed between the tips of the opened mitral valve leaflets. Measurements of Peak E and peak velocity of late diastolic transmitral flow were recorded. The DT E was measured as the time from Peak E to the end of the E wave at baseline. Summated E and A waves observed in 2 dogs with MVD (groups 1 and 2) were not measured. Duration of late diastolic transmitral flow was measured from the beginning to the end of the A wave. Pulmonary venous flow was recorded from the same left apical 4-chamber view, with minimal baseline filter, optimized velocity scale, and a pulsed-wave sample volume of 4 to 6 mm placed 5 to 10 mm within the pulmonary vein of the left caudal lung lobe. 22 Only the duration of late diastolic pulmonary venous flow reversal was measured. Pulsed-wave Doppler echocardiography-derived velocities of myocardial motion were recorded from an optimized apical 4-chamber view, with the structure of interest moving parallel to the ultrasound beam and a pulsed-wave sample volume of 5 to 6 mm placed in the lateral aspect of the mitral annulus. Frame rate during tissue Doppler studies was increased (> 160 frames/s) by narrowing the imaging sector. The Peak Ea Lat was measured. From a right parasternal tilted short-axis view or a left apical cranial view optimized for the right ventricular inflow tract, peak tricuspid regurgitation velocity was recorded when present. Variables calculated included the ratio of maximum left atrial dimension to aortic root dimension, E:IVRT (ie, ratio of Peak E in cm/s to IVRT in milliseconds), E:A, the ratio of the duration of the A wave to the duration of late diastolic pulmonary venous flow reversal, and E:Ea Lat. Left ventricular diastolic function was classified 20, 23 on the basis of E:A and qualified by use of E:Ea Lat as follows: class 1, normal pattern (1.0 ≤ E:A ≤ 2.0); class 2, relaxation delay pattern (E:A < 1.0); class 3, pseudonormal pattern (1.0 ≤ E:A ≤ 2.0), and class 4, restrictive pattern (E:A > 2.0). Class 1 and class 3 were discriminated by use of cutoffs of E:Ea Lat as follows: 11.0 for dogs with MVD and 9.0 for dogs with DCM. k,l In dogs > 10 years old, an E:A between 1.0 and 2.0 was considered pseudonormal transmitral flow as a physiologic age-related relaxation delay pattern would be expected in such dogs.
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Home monitoring of respiratory rate-Home monitoring of respiratory rate was done by the dog owners. At examination 1, a form was given to the clients and they were instructed to count the number of breaths per minute based on thoracic wall movements, with the dogs being at rest (almost asleep) or asleep and in sternal or lateral recumbency. The technique of measuring respiratory rate in a dog was demonstrated during examination 1. Date, time of day (morning, midday, and evening), and respiratory rate in breaths per minute were documented and the completed forms returned at examination 2. For statistical analysis, 5 values of respiratory rate were considered: respiratory rate in the hospital at examination 1, respiratory rate at home on the day after examination 1 (mean of 3 recordings), respiratory rate at home in the period between examinations 1 and 2 (midperiod; mean of 9 recordings taken on 3 consecutive days), respiratory rate at home on the day before examination 2 (mean of 3 recordings), and respiratory rate in the hospital at examination 2. If owners were unable to document respiratory rate 3 times a day, the mean respiratory rate of the counts provided was used for statistical analysis.
Statistical analysis-Statistical analyses were performed with commercially available software.
m-o All data were graphed, visually inspected, and also tested for normality by use of the Kolmogorov-Smirnov test or the Shapiro-Wilk test. Descriptive statistics were calculated, and frequencies or median and 5th and 95th percentiles were reported for individual variables. A paired t test or a Wilcoxon signed rank test was used for comparison of continuous data obtained at examinations 1 and 2 based on standard assumptions of parametric and nonparametric statistical tests. Proportions were compared by use of χ 2 analysis or the Fisher exact test. Differences of respiratory rate obtained at the hospital and during home monitoring were identified with repeated-measures ANOVA on ranks and the Holm-Sidak test for comparison to baseline (examination 1). Respiratory rate of dogs in groups 1 and 4 and dogs in groups 2 and 5 was compared by use of a t test or the Mann-Whitney rank sum test. Receiveroperating characteristic curve analysis was used to determine the diagnostic ability of heart rate, respiratory rate, NT-proANP concentration, NT-proBNP concentration, and various Doppler echocardiographic variables in the prediction of CHF at examination 2 (as determined by thoracic radiography) and to define optimal discrimination limits (diagnostic cutoff values) for such prediction. The area under the receiver-operating characteristic curve was used as a summary measure for diagnostic accuracy and is reported with 95% confidence intervals. Cutoff values were chosen on the basis of the highest of various combinations of sensitivity and specificity. Multivariate logistic regression was used to predict the qualitative dichotomous variable CHF absent or CHF present at examination 2 in dogs with MVD by fitting a logistic function to the independent (predictor) variables. Once variables with significant (P < 0.05) associations were identified, forward selection and best subsets regression analyses were performed to best identify the combination of variables that predicted CHF at examination 2 and to determine the contribution of individual variables to the final prediction model. As CHF was not found in any dog with DCM at examination 2, this procedure was not performed. Finally, to determine whether a decrease in respiratory rate to ≤ 40 breaths/min and an improvement of diastolic class were associated with resolution of CHF, the Fisher exact test was used. For all analyses, probabilities ≤ 0.05 were considered significant.
Results
Time between examinations 1 and 2 ranged from 5 to 14 days (Tables 1 and 2 ). There were 45 dogs with MVD: 21 in group 1 (dogs without clinical evidence of CHF), 17 in group 2 (responders to treatment of CHF), and 7 in group 3 (nonresponders to treatment of CHF). There were 18 dogs with DCM: 11 in group 4 (dogs without clinical evidence of CHF) and 6 in group 5 (responders to treatment of CHF); 1 dog with DCM died between examinations 1 and 2, and data for this dog were excluded from statistical analysis. Median (5th to 95th percentiles) age and body weight of dogs with MVD and DCM were 10 years (6 to 13 years) and 7 years (2 to 12 years) and 11 kg (24 lb; 4 to 36 kg [9 to 79 lb]) and 34 kg (75 lb; 13 to 57 kg [29 to 125 lb]), respectively. There was no significant difference in age and body weight between groups 1, 2, and 3 and between groups 4 and 5. There were 18 breeds in the groups of dogs with MVD, of which Cavalier King Charles Spaniels (n = 13) were overrepresented. Twenty-two dogs with MVD were female, and 23 dogs were male. There were 7 breeds in the groups of dogs with DCM, of which Doberman Pinschers (n = 9) were overrepresented. Nine dogs with DCM were female, and 8 dogs were male. At examination 1, 11 of 21 (52%) dogs of group 1 and 10 of 24 (42%) dogs of groups 2 and 3 were receiving long-term treatment with enalapril or benazepril. In groups 2 and 3, 12 of 24 (50%) dogs had received furosemide within the 12 hours prior to examination 1; however, uncontrolled CHF was still evident at the time of examination 1 on the basis of blinded interpretation of thoracic radiographs. At the time of initial examination, 1 dog of group 4 and 2 dogs of group 5 were receiving long-term treatment with enalapril or benazepril. In group 5, 2 dogs had received furosemide within the 12 hours prior to examination 1; however, these 2 dogs still had a diagnosis of CHF at the time of examination 1. See Table 1 for remainder of key. Table 2 -Median (5th to 95th percentiles) values for selected radiographic, blood biochemical, and Doppler echocardiographic variables in 17 dogs with DCM assessed at baseline and 6 to 14 days later. Figure 1 -Scatterplots representing changes in respiratory rate, serum NT-proBNP concentration, and E:Ea Lat from baseline (examination 1) to 5 to 14 days later (examination 2) in 21 dogs with preclinical MVD and no evidence of CHF at either examination (group 1; panels A, D, and G), 17 dogs with MVD and CHF evident at examination 1 but resolved CHF at examination 2 (group 2; panels B, E, and H), and 7 dogs with MVD and CHF evident at both examinations (group 3; panels C, F, and I). Figure 2 -Scatterplots representing changes in respiratory rate, serum NT-proBNP concentration, E:Ea Lat, and E:IVRT from examination 1 to examination 2 in 11 dogs with preclinical (occult) DCM with no evidence of CHF at either examination (group 4; panels A, C, E, and G) and 6 dogs with DCM and CHF evident at examination 1 but resolved CHF at examination 2 (group 5; panels B, D, F, and H).
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nate ( Measured variables in group 1 (ie, dogs with preclinical MVD with no evidence of CHF at either examination) did not change significantly from examination 1 to examination 2 (Figure 1 ; Table 1 ). Dogs with CHF at examination 1 but with resolution of CHF at examination 2 (group 2) had significant changes with regard to heart rate, diastolic class, respiratory rate, serum NT-proBNP concentration, and E:Ea Lat. Mean decrease in heart rate was 9 beats/min (8% decrease; range, 10% increase to 35% decrease). Doppler echocardiographic studies revealed that diastolic class was unchanged between examinations in 11 dogs and improved from restrictive (class 4) to pseudonormal (class 3) in 6 of 17 group 2 dogs. Respiratory rate recorded at the hospital decreased in 16 of 17 group 2 dogs by a mean of 19 breaths/min (32% decrease; range, 33% increase to 56% decrease) and was ≤ 40 breaths/min on the day prior to examination 2 in all group 2 dogs. Serum concentration of NTproBNP decreased in 14 of 17 group 2 dogs by a mean of 433 pmol/L (18% decrease; range, 133% increase to 28% decrease). Paradoxically, the E:Ea Lat increased in 14 of 17 group 2 dogs by a mean of 2.0 (14% increase; range, 64% increase to 15% decrease). In dogs with MVD and CHF present at both examinations (group 3), none of the variables except for E:IVRT and DT E were significantly different between examinations.
Measured variables in group 4 (ie, dogs with preclinical [occult] DCM with no evidence of CHF at either examination) did not change between examinations ( Figure 2 ; Table 2 ). Dogs with DCM and CHF at the time of examination 1 but with resolution of CHF at examination 2 (group 5) had significant differences between examinations with regard to IVRT, DT E , Peak E, E:A, diastolic class, respiratory rate, serum NT-proBNP concentration, E:Ea Lat, and E:IVRT. The IVRT and DT E each increased in 5 of 6 group 5 dogs by a mean of 18 milliseconds (60% increase; range, 0% change to 181% increase) and 26 milliseconds (42% increase; range, 0% change to 72% increase), respectively. Measurements of Peak E and E:A decreased in all group 5 dogs by a mean of 0.36 m/s (28% decrease; range, 13% decrease to 40% decrease) and 0.75 (28% decrease; range, 18% decrease to 40% decrease), respectively. Diastolic class improved in all group 5 dogs from restrictive (class 4) to pseudonormal (class 3). Respiratory rate recorded at the hospital, serum NT-proBNP concentration, E:Ea Lat, and E:IVRT decreased in all group 5 dogs by a mean of 27 breaths/min (49% decrease; range, 33% decrease to 55% decrease), 950 pmol/L (21% decrease; range, 4% decrease to 38% decrease), 5.2 (36% decrease; range, 3% decrease to 59% decrease), and 2.28 (52% decrease; range, 33% decrease to 75% decrease), respectively. The mean decrease in serum NT-proBNP concentration in group 5 dogs was not significantly different from the mean decrease in serum NT-proBNP concentration in group 2 dogs. Respiratory rate was ≤ 26 breaths/min on the day prior to examination 2 in all group 5 dogs.
Respiratory rates could not be determined for all dogs in the hospital setting; 3 dogs with MVD and 2 dogs with DCM were continually panting in the hospital. However, in the home environment, respiratory rate was successfully monitored for all dogs (Table 3) . In dogs with MVD and DCM that changed CHF status during the treatment period (groups 2 and 5), respiratory rate significantly decreased and was not different from that of dogs in groups 1 and 4 on the day before examination 2 (at home) or at the time of examination 2 (in hospital). In dogs with MVD that did not change CHF status during the treatment period (group 3), respiratory rate did not change. There was no difference between dogs of groups 1 and 4 or between dogs of groups 2 and 5 at any examination time point.
The sensitivity and specificity for predictors of CHF in dogs with MVD (groups 2 and 3) at examination 2 were determined (Table 4) . Respiratory rate taken by the owner at home on the day before examination 2 best predicted the main outcome of CHF (present or absent) with 100% accuracy when the decision threshold was 40 breaths/min. Multivariate logistic and best subsets regression analysis revealed that only respiratory rate as measured by the owner on the day before examination 2 predicted the binary outcome of presence or absence of CHF at examination 2 (R 2 = 0.67; P < 0.001; CHF = -X + [27.95 X respiratory rate]). The serum concentrations of NT-proBNP (P = 0.158), E:IVRT (P = 0.35), and diastolic class (P = 0.38) were not significant predictors of CHF within the multivariate model. Finally, the contingency table for examination 2 that used CHF (present or absent) and respiratory rate (> 40 breaths/ min or ≤ 40 breaths/min) in the analysis indicated that a change of CHF status between examinations 1 and 2 could be predicted by a change of respiratory rate (P = 0.018) in dogs with MVD (groups 2 and 3; Fisher exact test). By use of the same approach, a change of CHF status could not be predicted by a change in the Doppler echocardiography-derived diastolic class (P = 0.235) in the dogs with MVD.
Discussion
The purpose of this study was to examine the shortterm effects of treatment of CHF on clinical, hematologic, and Doppler echocardiographic markers of CHF. We evaluated the simple variable respiratory rate, laboratory tests measuring concentrations of circulating natriuretic peptides, and relatively more complicated Doppler echocardiographic variables of left ventricular filling. Our goal was to quantify changes in these variables that would be associated with successful treatment of CHF and to recommend clinically applicable decision thresholds. Dogs with CHF due to MVD and DCM often but not invariably respond to treatments that reduce left ventricular load or improve cardiac function, and knowledge of response patterns induced by treatment of CHF that follows clinical and radiographic status could help clinicians to tailor treatment and set quantitative targets for successful treatment. The results of this study support the following conclusions: in dogs with MVD, resolution of CHF is associated with a consistent decrease in respiratory rate and less predictively a decrease in serum NT-proBNP concentrations and Doppler echocardiography-derived diastolic functional class; in dogs with DCM, resolution of CHF is associated with a consistent decrease of respiratory rate and serum NT-proBNP concentration and with changes in multiple Doppler echocardiographic variables, including E:IVRT; there are similarities (ie, in respiratory rate) as well as differences (ie, in serum NTproBNP concentration and Doppler echocardiographic variables) in the responses of dogs with MVD, compared with that of dogs with DCM, following short-term treatment of CHF; and home monitoring of respiratory rate is a simple and seemingly accurate method for assessment of CHF status in dogs with MVD and DCM.
Measurement of circulating natriuretic peptides, in particular of NT-proBNP, has aided in the diagnosis of heart disease and CHF and in prognostication. 1, 2, 17, 19, 25 Blood natriuretic peptide concentrations depend mainly on volume load, ventricular filling pressure, and magnitude of ventricular remodeling and correlate with the state of neurohormonal activation in CHF. 1, 19, [26] [27] [28] Low circulating NT-proBNP concentration has high negative predictive value in dogs and people, making it a useful ruleout test for CHF, particularly in populations in which frequency of heart failure is expected to be high. 2, 19, 26, 27, 29 As reported in this study and elsewhere, 1, 8, 17, 19 dogs with acute CHF have consistently high serum NT-proBNP concentrations with considerable interindividual variation. However, little is known about the response of circulating natriuretic peptides to short-term treatment of acute CHF in dogs. Based on the established triggers for release and the short half-life, one could hypothesize that aggressive ventricular unloading associated with a decrease in ventricular filling pressures and resolution of CHF would be accompanied by a fast and considerable decrease in serum NT-proBNP and NT-proANP concentrations. 26, 30, 31 In contrast, in dogs with preclinical disease, the natriuretic peptide concentrations should change minimally if at all over a comparable period, which is a finding confirmed by this study. However, in dogs with MVD and DCM, serum NT-proANP concentration did not change significantly between examinations despite improvement of CHF status. This negates the value of this peptide for assessing short-term response to treatment of acute CHF. In contrast, serum NT-proBNP concentrations did decrease in 14 of 17 dogs with MVD of group 2 (mean decrease, 433 pmol/L) and in all 6 of the dogs with DCM of group 5 (mean decrease, 950 pmol/L). There was no significant difference in the relative change between groups from examination 1 to examination 2 (mean decrease, 18% in group 2 and 21% in group 5). Moreover, in dogs with MVD whose CHF status did not improve with treatment (group 3), median serum NT-proBNP concentration did not change (P = 0.26). Thus, results of this study suggest that monitoring short-term treatment of CHF through serum NT-proB-NP concentration could be of clinical value and that a decrease in serum NT-proBNP concentration of ≥ 20% Table 4 -Area under the receiver-operating characteristic curves of selected physiologic and echocardiographic variables in the prediction of CHF at examination 2 in dogs with MVD and CHF at examination 1 (groups 2 and 3).
within a week of treatment would most likely indicate successful therapy. This is a smaller decrease in circulating NT-proBNP concentration than observed in people with acute CHF where serum NT-proBNP concentration decreased by a mean of 40% 30 and 42% over a comparable treatment period. 32 Studies in dogs 33, 34 and human patients [26] [27] [28] [29] [30] [35] [36] [37] [38] have led to the conclusion that shortterm changes of serum NT-proBNP concentration during intense unloading treatment depend not only on the acute improvement of hemodynamics, but also on other cardiac and noncardiac factors. It is likely that some dogs will respond to treatment of acute CHF and still maintain activation of neurohormonal systems. Moreover, a decline in renal function commonly seen with CHF treatment might hinder the anticipated decrease of circulating NT-proBNP concentration, although the latter is unlikely to have affected the results of this study owing to the minor degree of azotemia observed only in a low number of dogs. 33, 34 These situations render NT-proBNP a less-ideal variable to indicate hemodynamic improvement. 26 The value of NT-proBNP for therapeutic decision making in dogs with CHF might be enhanced if a basal serum NT-proBNP concentration was known for an individual dog. 28 This difference could then serve as a treatment target for titration of load-reducing drugs. Based on the results of this study, individualization of heart failure treatment from a single value of serum NT-proBNP concentration 35, 36 cannot be recommended; however, the test may provide incremental predictive power for therapeutic decision making. 37 The determination of respiratory rate and the pattern of ventilation have a long-standing clinical basis for identification of cardiorespiratory disorders. However, the short-term effects of treatment on the respiratory rate of dogs with CHF have not yet been prospectively studied. Furthermore, the use of respiratory rate to discriminate dogs with and without CHF has not been reported to our knowledge. Respiratory rate is controlled by involuntary (central regulation, reflex-mediated signaling from the lungs, and peripheral vascular chemoreceptor responses) as well as voluntary mechanisms. Due to increased pulmonary venous pressure and fluid accumulation found with left-sided CHF, 38 the lungs become stiffer, pulmonary stretch receptors are stimulated, and respiration becomes insufficient, leading to hypoxemia and acidosis, ultimately causing an increased effort and frequency of breaths. 12, [38] [39] [40] In the present study, all dogs with CHF had high respiratory rate and resolution of heart failure was accompanied by a predictable decrease of respiratory rate to values equivalent to or below the respiratory rate of dogs without clinical signs of CHF. In the hospital, respiratory rate decreased in 16 of 17 dogs of group 2 (mean decrease, 19 breaths/min) and in all 6 dogs of group 5 (mean decrease, 27 breaths/min), with no significant difference between groups from examination 1 to examination 2 (mean decrease, 32% in group 2 and 49% in group 5; P = 0.39). Moreover, in dogs that did not improve in CHF status (group 3), median respiratory rate did not change (P = 0.55). It is of interest to note that respiratory rate measured by the owner in the home environment was most accurate for prediction of CHF status at examination 2. In this regard, respiratory rate outperformed the laboratory and Doppler echocardiographic variables analyzed in this study, whether or not respiratory rate was taken at home or measured in the hospital. By use of a diagnostic cutoff of ≤ 40 breaths/ min for dogs with MVD and ≤ 26 breaths/min for dogs with DCM on the day before examination 2, the presence or absence of CHF could be predicted with high accuracy. The clinical relevance of this is that in addition to predicting successful short-term treatment of CHF, the respiratory rate measured at home may allow both clinicians and owners to more accurately tailor home treatment to a target respiratory rate and to avoid excessive or insufficient diuresis. This study suggests that veterinarians should instruct owners to monitor respiratory rate and that respiratory rate is useful for both diagnosis and management of dogs with CHF.
A high ventricular filling pressure plays a pivotal role in the underlying pathophysiologic changes of acute decompensated heart failure, and the development of cardiogenic pulmonary edema is predicted largely by the magnitude of volume overload and resulting increase in these pressures. 29, 30, 32, 38 In recent validation studies 9, 11 with laboratory dogs, we identified E:IVRT, IVRT, and diastolic functional class as variables most useful in the prediction of high filling pressures and CHF. Moreover, we also identified E:IVRT as the single best Doppler echocardiographic index for noninvasive tracking of decreasing filling pressures following furosemide administration to dogs with pacing-induced CHF. 11 The results of this study support the contention that resolution of CHF is associated with predictable changes in certain Doppler echocardiographic variables; however, the response differs in dogs with MVD, compared with that of dogs with DCM.
In dogs with MVD, Doppler echocardiographic indices were not particularly useful in predicting a radiographic response to treatment and were inferior to both respiratory rate and circulating NT-proBNP concentrations. Improvement of CHF status was associated with a change of functional diastolic class from restrictive to pseudonormal in 6 of 17 dogs, whereas there was no change of diastolic class in the remaining dogs. Considering there are only 3 classes of diastolic dysfunction defined by this system, rather large changes are needed to improve from one functional class to another. 41 Furthermore, in advanced MVD, left ventricular filling is influenced mainly by volume overload and is typically accompanied by normal or enhanced global left ventricular systolic function. This is fundamentally different from DCM 42 and makes Doppler echocardiography less applicable for the prediction of high left ventricular filling pressures and CHF in the setting of volume-overload dominant heart failure. 41, 43 Pseudonormal and even restrictive left ventricular filling may primarily result from marked volume overload as found in dogs with rapid volume loading and pacing-induced CHF. 9, 42, 44 In this context, the paradoxical changes of E:Ea Lat observed in dogs with MVD merit discussion. The E:Ea Lat ratio has been studied intensively over the past decade and identified as one of the most reliable Doppler echocardiographic indices of left ventricular filling pressure in dogs [45] [46] [47] and people 48, 49 with heart failure and left ventricular systolic dysfunction. Thus, the expectation would be that with resolution of CHF, SMALL ANIMALS E:Ea Lat would decrease. To the contrary, 14 of 17 dogs with MVD that improved CHF status actually increased E:Ea Lat (by a mean of 2.0). This finding underscores the often neglected load dependency of early diastolic lateral mitral annulus motion, particularly in situations where preload is high and left ventricular systolic function is normal or enhanced. 9, 45, 50 The clinical importance of this finding is that the E:Ea Lat, although often touted as a predictor of high filling pressures and CHF, is a poor choice in dogs with MVD. Similar findings have been reported from studies 37, 42, 44, 50, 51 in people with primary degenerative MVD.
In dogs with DCM, numerous Doppler echocardiographic indices were useful in predicting resolution of CHF. These indices were diagnostically comparable to respiratory rate and superior to NT-proBNP in these dogs, in particular the IVRT (mean increase, 18 milliseconds or 60%), E:IVRT (mean decrease, 2. , also changed in accordance with a change of CHF status. From these data, it appears that a variety of Doppler echocardiographic variables may be useful in predicting response to treatment of CHF in dogs with DCM. A change of diastolic class and a prolongation of IVRT and a decrease in E:IVRT both by > 50% from baseline may indicate a change of CHF status or at least a significant improvement of the hemodynamic situation. Doppler echocardiography may be especially useful 13 in situations where clinical signs are ambiguous, a reliable estimate of respiratory rate is absent, or thoracic radiographs are unavailable, inconclusive, or obscured by concurrent lung disease.
The E:IVRT and IVRT have only recently been studied as indices of filling pressure and CHF. 9, 11 In DCM, where impaired systolic function is dominant, IVRT shortens or prolongs in proportion to an increase or decrease of filling pressure. 9, 11, 43, 51, 52 Because high filling pressure is associated with both increased Peak E and decreased IVRT, the E:IVRT should be high in dogs with DCM and CHF and should decline with resolution of CHF. 9, 11, 41, 44, 53, 54 Both IVRT and the Peak E (and thus E:IVRT) are easy to measure with standard echocardiographic equipment in comparison to many other Doppler echocardiographic indices used in clinical practice and should be useful in assessing dogs with DCM.
A number of limitations of this study can be identified. Thoracic radiography was used as the reference standard for the diagnosis of CHF and group assignment. However, the accuracy of thoracic radiography in the diagnosis of CHF may be limited related to subjectivity of interpretation, radiographic technique, concurrent disease, observer variation, 20, 39, [55] [56] [57] and other factors. 6, 7, 39 Moreover, the dichotomous outcome measure chosen (CHF present or absent) did not permit further subgroup analysis, which may have led us to overlook other associations between target variables and treatment. The small sample size, especially in dogs with DCM and dogs of group 3, may have resulted in an underpowered study. The period between examination 1 and examination 2 ranged from 5 to 14 days, and it is possible that this may have affected our results relative to the temporal relationship between predictor variables and outcome. Treatment of CHF was individualized, and no attempts were made to standardize drugs or dosages. Echocardiography and determination of serum NT-proBNP concentration were performed only twice in each dog, neglecting circadian and dayto-day fluctuations of hemodynamics and natriuretic peptides. 58, 59 Home monitoring of respiratory rate was performed by dog owners, and the accuracy of their observations cannot be ensured. Respiratory rate may also be influenced by effects other than cardiorespiratory, including pain, excitement, obesity, and ambient and body temperature. The Doppler echocardiographic variables and the classification method of left ventricular diastolic function were chosen on the basis of human studies 41 and data obtained from studies in dogs. 10, 11, 24 However, the classification system used in this study
has not yet been prospectively validated against a goldstandard measure of left ventricular diastolic function. Age, heart rate, and body weight were not specifically considered, although these variables may influence left ventricular diastolic function. 24 Azotemia was present in some dogs and could have affected NT-proBNP results. 33 Finally, an assessment of repeatability and reproducibility of measurements was not performed. However, respiratory rate was assessed at several points in time and the mean calculated, natriuretic peptides were analyzed in duplicate and the mean also calculated, and intra-and interobserver measurement variability of Doppler echocardiographic variables in our laboratory is good as recently reported. 20 Despite these limitations, a number of conclusions can be drawn. Resolution of CHF can be predicted by monitoring respiratory rate, selected Doppler echocardiographic variables of left ventricular filling, and serum NT-proBNP in dogs with DCM and respiratory rate, serum NT-proBNP, and less reliably Doppler echocardiographic variables of left ventricular filling in dogs with MVD. Dilated cardiomyopathy and MVD are different disorders, and disease-specific targets are needed to discriminate dogs with and without CHF. Home monitoring of respiratory rate is simple and very useful in the assessment of CHF in dogs with either DCM or MVD. The use of respiratory rate, analysis of serum NT-proBNP concentration, and transthoracic Doppler echocardiography for clinical guidance in the treatment of CHF merits further study. 
